Skip to main content
. 2016 Nov 25;8(3):5603–5618. doi: 10.18632/oncotarget.13629

Figure 6. A schematic model of the VEGF-C/VEGFR3-mediated KRAS/MAPK-YAP1/Slug pathway in skin cancer progression.

Figure 6

In skin cancer cells, VEGF-C/VEGFR3 signaling activates the KRAS/MAPK axis to up-regulate YAP1 and Slug expression, further enhancing cell mobility and cancer stemness. Anti-VEGFR3 peptide functions as a repressor and could be a therapeutic strategy.